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This talk will:
• Introduce: 
• The bleeding disorder Hemophilia A
• The Blood Coagulation Cascade 
• Blood Coagulation Factor VIII (FVIII) protein
• 3-D molecular structure of novel human/porcine 
chimeric FVIII for Hemophilia A therapy 
• Implications for future research
Central Dogma of Biology
National Human Genome Research Institute (NHGRI)
Hemostasis 




formation of FXa by 
200,000 times.
Shen et. al, Blood, 2008, 111, 1240-1257
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Hemophilia Degrees of Severity (% FVIII or FIX)
• X-linked disease that affects 1 in 5000 males worldwide
• Hemophilia A replacement therapy with recombinant FVIII
Resolution: 3.7Å
SpaceGroup: 41212
• ~30% patients receiving FVIII concentrate 
replacement therapy acquire an inhibitory 
alloantibody.




Bray et al, Blood, 1994, 83 (9), 2428-2435 






















Inhibitory Antibody Concentration (mg/mL)
Astermark, Thrombosis Research, 2011, 127, S6-S9
Immune Tolerance Induction (ITI)
Brackmann, H.h., and J. Gormsen. The Lancet, 1977, 310, p.933.
Human / Porcine Chimeric FVIII (HP47)




• hFVIII expresses poorly. 
[Serum] = ~0.5nM 
• Recombinant porcine FVIII 
displays increased cellular 
secretion
• Human/Porcine Chimera as 
high output protein therapeutic
• HP47 demonstrates higher 









• Assess model agreement to 
electron density with R factors
• Rwork and Rfree




• ~85% of the 1467aa HP47 sequence built into model
Quality of the current model
• Rwork: 0.1972
• Rfree: 0.2863
• Ramachandran outliers: 10.40%
• Space Group: P21
• At 3.2Å, highest resolution FVIII model to date
• More confidently rebuild sections
Improvements to the Human Model FVIII
2008 FVIII Structure (PDB: 2R7E) Newly refined FVIII Structure
A1 A2 A3 C1 C2Human FVIII
New human/porcine FVIII structure
Improvements to the Human Model FVIII
Newly refined FVIII Structure
A1 A2 A3 C1 C2Human FVIII
New human/porcine FVIII structure
• Enhance basic understanding of 
FVIII’s function in coagulation
• Develop more effective 
Hemophilia A therapeutics
• Hemophilia A is a X-linked disease caused by a lack of blood 
coagulation factor VIII (FVIII) protein.
• Patients who develop an immune response to FVIII rely on large 
quantities of improved therapeutics.
• Determined crystal structure of novel Human/Porcine Chimeric 
therapeutic. Improved human FVIII protein model.
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